16 slides from Inventurus Knowledge Solutions's earnings presentation, Feb 5, 2025
Slide 1: Cover letter to stock exchanges: Investor Presentation
February 5, 2025 BSE Limited National Stock Exchange of India Limited The Listing Department The Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, G Block, 25th Floor, Dalal Street Bandra Kurla Complex Fort, Mumbai 400 001 Bandra (East), Mumbai 400051 Maharashtra, India Maha
Slide 2: IKS Health Q3 FY25 Investor Presentation
IKS Health Q3 FY 25 Investor Presentation 1
Slide 3: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 4: IKS Health - a comprehensive healthcare enablement platform empowering provider organizations
IKS Health - a comprehensive healthcare enablement platform empowering provider organizations US$4.8tn US$222bn / US$34bn 8% / 12% Total TAM / Outsourced Market US Healthcare TAM / Outsourced Market Addressable Expenditure (CY2023) CAGR (2023-2028E) (CY2023) Market1,2 The only Comprehensive platform
Slide 5: IKS Health enables care transformation across the patient journey
IKS Health enables care transformation across the patient journey Automation Level Automation Level Automation Level Automation Level Optimized Patient Patient Prospective Pre-Visit Scheduling Financial Engagement Clinical Chart Clearance Hub Reviews Automation Level Automation Level Automation Leve
Slide 6: Strong growth while delivering outsized margin expansion
Strong growth while delivering outsized margin expansion Deep Client Globally Diversified Growth At Scale Strong Margin Profile Relationships Workforce INR 6572 mn 450+ 31% 13,149 Revenue from Enterprise level EBITDA Total Employees Operations customers 16% INR 2,724 mn / 42% 20% 2524 / 491 YoY growth
Slide 7: 3 large client wins including a pathbreaking platform deal
3 large client wins including a pathbreaking platform deal Palomar Health and Palomar Health Medical Group partner with IKS Health to leverage cutting-edge healthcare technology and services to drive a holistic transformation that will enable a wide-range of clinical, operational and financial benefit
Slide 8: Scribble Now
With the launch of Scribble Now, IKS Health has the most comprehensive clinical documentation portfolio Scribble Scribble Scribble Scribble Scribble Swift Now Live Transcribe Pro Virtual Live Medical Speech Recognition Power of GenAI and Power of GenAI AI Only Scribing Scribing for clinical Technolo
Slide 9: IKS Health is embracing the next frontier in enterprise autonomy
IKS Health is embracing the next frontier in enterprise autonomy The next chapter in our platform evolution: With our success of Gen-AI adoption in 2024, we have started making the shift to true autonomy with an Agentic AI approach Agentic-AI led Automation Level of automation / business impact (Man
Slide 10: Awards and Recognition
Awards and Recognition 2024 Black Book Market Surveys Top Ranked for Clinical Documentation and Medical Coding Services Awards - August 2024 2025 Best in KLAS for Medical Transcription Services - February 2025 The M&A Advisor: 15th International M&A Awards Healthcare/ Life sciences deal of the year
Slide 11: Q3 FY25: Financial Highlights
Q3 FY25: Financial Highlights Revenue EBITDA INR Mn INR Mn 2.2% QoQ 5.7% QoQ 15.9% YoY 24.3% YoY 28.5% 29.5% 30.5% PAT Adjusted PAT* INR Mn INR Mn 14.8% QoQ 12.8% QoQ 17.9% 17.6% 19.7% 27.7% YoY 19.6% 20.1% 22.1% 30.6% YoY *Adjusted PAT is adjusted for amortization of intangible assets recognised on
Slide 12: Improving EPS and maintaining high ROE
Improving EPS and maintaining high ROE EPS ₹ ROE % EPS is calculated as profit for the period divided by weighted average Return on Equity is calculated as profit for the period divided by total number of equity shares as defined in IND AS 33. equity at the end of the period. 11
Slide 13: Strong cash generation supporting growth aspirations
Strong cash generation supporting growth aspirations OCF & FCF Net Debt INR Mn INR Mn 6,663 Cash flow and net debt has been adjusted for (1) IPO expenses paid during the quarter Rs 244 mn which have been subsequently recovered in Q4 FY 25 from the Selling shareholders and (2) a one time payment in th
Slide 14: Financials - Summary INR millions
Financials - Summary INR millions INR Mn Particulars Q3 FY 25 Q2 FY 25 QoQ% Q3 FY 24 YoY% 9M FY 25 9M FY 24 YoY% Revenue 6,572 6,428 2.2% 5,671 15.9% 19,400 11,980 61.9% Other Income - Operating* 192 7 2547.7% (8) -2415.1% 238 (2) -9958.1% Employee benefit expense excluding ESOP 3,769 3,587 5.1% 2,8
Slide 15: Other KPI Metrics
Other KPI Metrics Particulars Q3 FY 25 Q2 FY 25 Q3 FY 24 Annualised Adjusted EBITDA per employee* 0.64 0.56 0.64 Revenue from Top 10 customers INR mn 2,724 2,300 2,386 Contribution from top 10 customers 41.4% 35.8% 42.1% Revenue from Top 5 customers INR mn 1,806 1,413 1,521 Contribution from top 5 c
Slide 16: Join the Movement
Join the Movement Grow, Scale, Thrive